Koninklijke DSM N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 14 feb 2007 - 08:01
- Statutory name Koninklijke DSM N.V.
- Title DSM achieves record sales and operating profit in 2006, ahead of Vision 2010 objectives
- Comments • Operating profit for 2006 EUR 835 million, 6% higher than in 2005. • Net profit EUR 547 million, up 4% from 2005. • Solid volume growth (5%), especially in Performance Materials (9%). • Proposed dividend EUR 1.00 per ordinary share. • Outlook: Operating profit in 2007 expected to be lower than in 2006, but on track with Vision 2010. DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform. Royal DSM N.V. and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announce fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform.
|200702140000000003_03-E-07-DSM and Crucell-PERC6 breakthrough.pdf|
|200702140000000003_04-E-07-DSM FY Results 2006.pdf|
Date last update: 15 November 2019